<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00388804</url>
  </required_header>
  <id_info>
    <org_study_id>2003-0819</org_study_id>
    <nct_id>NCT00388804</nct_id>
  </id_info>
  <brief_title>External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer</brief_title>
  <official_title>Randomized Trial of External Beam Radiation With or Without Short-Course Hormonal Therapy in Intermediate Risk Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  To assess the possible improvement in prostate specific antigen (PSA) outcome of short&#xD;
           course androgen suppression therapy in conjunction with dose-escalation intensity&#xD;
           modulated radiation therapy (IMRT), 3D conformal radiation therapy (3D-CRT), or proton&#xD;
           therapy over IMRT, 3D-CRT, or proton therapy alone in prostate cancer patients&#xD;
           traditionally considered at intermediate risk for PSA failure following conventional&#xD;
           local therapy. PSA failure will be the primary endpoint.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess local control, freedom from distant metastasis, and overall survival.&#xD;
&#xD;
        -  To study the impact of radiation therapy and/or hormone therapy on health-related&#xD;
           quality of life measures using the Expanded Prostate Cancer Index Composite-Short Form&#xD;
           12-American Urological Association Symptom Index (EPIC-SF12-AUASI:&#xD;
           http://roadrunner.cancer.med.umich.edu/epic/).&#xD;
&#xD;
        -  To assess prognostic value of pretreatment serum testosterone as well as the decrease in&#xD;
           hemoglobin from neoadjuvant hormone therapy.&#xD;
&#xD;
        -  To assess prognostic value of pretreatment biomarkers on subsequent post-treatment&#xD;
           clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior patient studies have shown that short-term hormone therapy (about 4 months) before and&#xD;
      during radiation therapy can benefit patients with bulky tumors or locally-advanced prostate&#xD;
      tumors. These prior results have been used to justify a potential benefit for using&#xD;
      short-term hormone therapy combined with radiation therapy for patients with less bulky or&#xD;
      less advanced prostate cancers. However, the combination of hormone therapy and radiation has&#xD;
      not been shown to definitively benefit patients with your level of prostate cancer.&#xD;
      Furthermore, these older studies used relatively low doses of radiation by today's standards,&#xD;
      and hormone therapy may be of no benefit when using higher doses of radiation. Researchers&#xD;
      want to study the use of combination hormone therapy and radiation therapy in the treatment&#xD;
      of your level of prostate cancer.&#xD;
&#xD;
      If you are eligible to take part in this study, you will be randomly assigned (as in the toss&#xD;
      of a coin) to one of 2 treatment groups. There is an equal chance of being assigned to either&#xD;
      treatment group.&#xD;
&#xD;
      If you are assigned to Group 1, you will receive high-dose radiation treatment given over&#xD;
      about 8 1/2 weeks. During this period, you will receive up to 42 treatments, 5 days per week&#xD;
      with 2 days rest in between. There will be no treatment on weekends. This is the current&#xD;
      standard schedule of treatment for prostate cancer patients. A radiation treatment planning&#xD;
      session will be done before the actual radiation treatments. This planning session will be&#xD;
      used to get images of your prostate and other pelvic organs to help plan the radiation&#xD;
      fields. The planning session involves a computed tomography (CT) scan that takes about 40-45&#xD;
      minutes. During this time, about 3 special, permanent tattoo marks will be placed on your&#xD;
      skin using ink. The tattoo marks will help with daily setup and positioning of the radiation&#xD;
      fields. These marks are small and about the size of a freckle.&#xD;
&#xD;
      If you are assigned to Group 2, you will receive the same radiation therapy as participants&#xD;
      in Group 1, but you will also receive hormone therapy with bicalutamide (Casodex) and either&#xD;
      leuprolide (Lupron) or goserelin (Zoladex). The hormone therapy includes a total of 2&#xD;
      injections or shots (leuprolide or goserelin) given every 3 months and a pill (bicalutamide)&#xD;
      that is taken once per day for the first 21 to 30 days. Flutamide, which is taken three times&#xD;
      per day for the first 21-30 days, may be used instead of bicalutamide. The choice of hormone&#xD;
      therapy will be left up to your treating physician. You will receive hormone therapy for a&#xD;
      full 6 months. Hormonal treatment will begin about 2 months before radiation therapy is due&#xD;
      to start and continue for 2 months during radiation therapy, with the last phase of hormone&#xD;
      treatment for 2 months after radiation therapy.&#xD;
&#xD;
      No matter which group you are assigned to, you will be given questionnaires to study&#xD;
      health-related quality of life. These questionnaires will take about 15 minutes to complete&#xD;
      and will be given to you before therapy begins. Within 1-2 weeks before starting radiation&#xD;
      therapy, you will answer a health-related quality of life questionnaire (Expanded Prostate&#xD;
      Cancer Index Composite-SF12-AUASI). Participants who are receiving hormonal therapy will also&#xD;
      be given this questionnaire within one week before hormonal therapy. During radiotherapy, you&#xD;
      will be examined every week, and severe side effects and reactions will be recorded using the&#xD;
      modified acute toxicity scale. During radiotherapy, you also will be given the EPIC-26 Short&#xD;
      Form at Weeks 4 and 8.&#xD;
&#xD;
      After you finish radiation therapy, you will be given the EPIC-SF12-AUASI every 3 months for&#xD;
      the first year, every 6 months for the next 2 years, and then once a year after that. This&#xD;
      may be done in person, by phone or by mail.&#xD;
&#xD;
      Prostate specific antigen (PSA) and testosterone levels will be checked before therapy&#xD;
      begins. These blood tests will require about 1 teaspoon of blood. They will be checked before&#xD;
      radiation therapy begins, but will not be checked during your radiation treatment. Your PSA&#xD;
      and testosterone levels will be rechecked at 3 to 6 month intervals after the radiation&#xD;
      therapy is done for the first 2 years. PSA will be checked every 6 months for the Years 3 and&#xD;
      4, and once a year for Year 5.&#xD;
&#xD;
      If you have worsening of disease or have intolerable side effects, you may elect to remove&#xD;
      yourself from the prescribed treatment, but you may still be followed as part of the study.&#xD;
&#xD;
      You will be asked to return for follow-up testing in the form of physical exam every 6 months&#xD;
      for the first 2 years and once each year after that. The purpose of the follow-up visits and&#xD;
      tests is to check the response of your cancer to treatment. If the PSA or physical exam shows&#xD;
      that the disease has not gone away completely or has come back, you may have repeat staging&#xD;
      with a bone scan, pelvic CT or magnetic resonance imaging (MRI), and repeat prostate biopsy.&#xD;
&#xD;
      You will be watched for the condition of your disease for at least 4-5 years with follow-up&#xD;
      visits and PSA tests. If you are willing to return for follow-up visits beyond 5 years, then&#xD;
      you will continue to receive long term follow-up and be observed and advised about your&#xD;
      illness, according to your individual needs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual.&#xD;
  </why_stopped>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate Specific Antigen (PSA) Failures</measure>
    <time_frame>3 months up to 2 years</time_frame>
    <description>Baseline + Post-radiation PSA levels at three month intervals for initial two years then every 6 months thereafter. Participants with a rising PSA and no evidence of local or distant recurrence considered PSA failures.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>RT Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT Group 2 + Hormone Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.</description>
    <arm_group_label>RT Group 1</arm_group_label>
    <arm_group_label>RT Group 2 + Hormone Therapy</arm_group_label>
    <other_name>RT</other_name>
    <other_name>XRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>50 mg By Mouth (PO) Daily</description>
    <arm_group_label>RT Group 2 + Hormone Therapy</arm_group_label>
    <other_name>Casodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <description>22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month</description>
    <arm_group_label>RT Group 2 + Hormone Therapy</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month</description>
    <arm_group_label>RT Group 2 + Hormone Therapy</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flutamide</intervention_name>
    <description>250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.</description>
    <arm_group_label>RT Group 2 + Hormone Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.</description>
    <arm_group_label>RT Group 1</arm_group_label>
    <arm_group_label>RT Group 2 + Hormone Therapy</arm_group_label>
    <other_name>Survey</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Biopsy proven prostate cancer within last 12 months. Pathology must be reviewed at&#xD;
             M.D. Anderson Cancer Center (MDACC).&#xD;
&#xD;
          2. 1992 American Joint Committee on Cancer (AJCC) clinical stage T1c-2b on digital rectal&#xD;
             exam with biopsy Gleason sum of 7 and Prostate-Specific Antigen (PSA) &lt; 20 ng/mL (i.e.&#xD;
             PSA 19.99 ng/mL or less)&#xD;
&#xD;
          3. 1992 AJCC clinical stage T2b on physical exam with biopsy Gleason sum of 7 or less&#xD;
             and/or PSA &lt; 20 ng/ml&#xD;
&#xD;
          4. 1992 AJCC clinical stage T1c-2b on digital rectal exam with biopsy Gleason sum of 7 or&#xD;
             less and PSA &gt; 10 but less than 20 ng/ml (i.e. 10.01-19.99 ng/mL). PSA used for&#xD;
             protocol eligibility should be obtained within 30 days of protocol enrollment.&#xD;
&#xD;
          5. No evidence of metastatic disease on bone scan within 3 months of study enrollment.&#xD;
&#xD;
          6. No evidence of metastatic disease on pelvic computed tomography (CT) or magnetic&#xD;
             resonance imaging (MRI) within 3 months of study enrollment.&#xD;
&#xD;
          7. Zubrod performance status &lt; 2.&#xD;
&#xD;
          8. Must be able to understand protocol and adhere to follow-up initially at 3 months&#xD;
             post-radiation and then at 6 month intervals for first two years and annually&#xD;
             thereafter.&#xD;
&#xD;
          9. Patient must be able to undergo adequate daily trans-abdominal ultrasound localization&#xD;
             (B.A.T.) or other image-guided localization of the prostate during radiation course.&#xD;
&#xD;
         10. Patients will be allowed to participate in other protocols if they are eligible and&#xD;
             the other protocols do not interfere with participation in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who do not meet the inclusion criteria. Specifically, patients with all the&#xD;
             following features: clinical T1c-2a and Gleason sum of 6 and PSA &lt;/= 10 ng/ml.&#xD;
             Patients with one or more of the following features: clinical T2c, or Gleason 8-10, or&#xD;
             PSA &gt; 20 ng/ml are not eligible.&#xD;
&#xD;
          2. Prior androgen suppression therapy. (Prior finasteride and saw palmetto allowed but&#xD;
             must be discontinued prior to enrollment. Biopsy and PSA must be documented prior to&#xD;
             finasteride use.)&#xD;
&#xD;
          3. Previous or concurrent malignancies other than basal or squamous cell skin cancers&#xD;
             unless disease-free for 5 years or more.&#xD;
&#xD;
          4. Prior pelvic radiation or chemotherapy. Patients who received chemotherapy for&#xD;
             non-prostate cancer malignancies over 5 years prior will be eligible.&#xD;
&#xD;
          5. Prior or planned radical prostate surgery.&#xD;
&#xD;
          6. Patients with clinical evidence or biopsy-proven extracapsular extension, seminal&#xD;
             vesicle involvement, or lymph node involvement will be excluded. Patients with&#xD;
             radiographic evidence of nodal or bone metastasis will be excluded.&#xD;
&#xD;
          7. Other histologies such as small cell carcinoma, sarcomatoid or ductal variants are not&#xD;
             eligible.&#xD;
&#xD;
          8. Patients with any Gleason grade 5 disease on biopsy will not be eligible.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew K. Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>October 15, 2006</study_first_submitted>
  <study_first_submitted_qc>October 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2006</study_first_posted>
  <results_first_submitted>June 29, 2012</results_first_submitted>
  <results_first_submitted_qc>June 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2012</results_first_posted>
  <last_update_submitted>June 29, 2012</last_update_submitted>
  <last_update_submitted_qc>June 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>External Beam Radiotherapy</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Hormone Therapy</keyword>
  <keyword>Bicalutamide</keyword>
  <keyword>Casodex</keyword>
  <keyword>Leuprolide</keyword>
  <keyword>Lupron</keyword>
  <keyword>Goserelin</keyword>
  <keyword>Zoladex</keyword>
  <keyword>Flutamide</keyword>
  <keyword>EBRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 02/16/2005 to 09/08/2010. All recruitment was at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 39 enrolled participants, one participant was excluded from the trial before assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RT Group 1</title>
          <description>Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.</description>
        </group>
        <group group_id="P2">
          <title>RT Group 2 + Hormone Therapy</title>
          <description>Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RT Group 1</title>
          <description>Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.</description>
        </group>
        <group group_id="B2">
          <title>RT Group 2 + Hormone Therapy</title>
          <description>Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" lower_limit="53" upper_limit="78"/>
                    <measurement group_id="B2" value="64.5" lower_limit="48" upper_limit="73"/>
                    <measurement group_id="B3" value="65.3" lower_limit="48" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prostate Specific Antigen (PSA) Failures</title>
        <description>Baseline + Post-radiation PSA levels at three month intervals for initial two years then every 6 months thereafter. Participants with a rising PSA and no evidence of local or distant recurrence considered PSA failures.</description>
        <time_frame>3 months up to 2 years</time_frame>
        <population>One person was not treated and therefore excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RT Group 1</title>
            <description>Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.</description>
          </group>
          <group group_id="O2">
            <title>RT Group 2 + Hormone Therapy</title>
            <description>Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Specific Antigen (PSA) Failures</title>
          <description>Baseline + Post-radiation PSA levels at three month intervals for initial two years then every 6 months thereafter. Participants with a rising PSA and no evidence of local or distant recurrence considered PSA failures.</description>
          <population>One person was not treated and therefore excluded from the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RT Group 1</title>
          <description>Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.</description>
        </group>
        <group group_id="E2">
          <title>RT Group 2 + Hormone Therapy</title>
          <description>Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine transaminase (ALT)</sub_title>
                <description>Grade I elevated ALT, no relationship to protocol treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Aspartate transaminase (AST)</sub_title>
                <description>Grade I elevated AST, possibly related to protocol treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <description>2 of 17 (11.8%) in Arm 1 experienced urinary frequency&#xD;
1 of 21 (4.7% in Arm 2 experienced urinary frequency</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Lee, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer</organization>
      <email>lhamblin@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

